Sigma-Aldrich Signs Licensing Agreement with Epigentek Group
News Jun 14, 2007
Under this agreement, Sigma-Aldrich gains rights to core Epigentek technologies, including DNA modification, methylation quantitation and protein/DNA interaction. This agreement is exclusive in the U.S. and co-exclusive globally.
"Sigma-Aldrich has identified Epigenetics as a growing area of interest and research for heritable diseases such as cancer, Alzheimer's and many others," said Keith Jolliff, Director of Genomics and Functional Genomics at Sigma-Aldrich. "We see the licensing with Epigentek as the right fit to our ongoing commitment to provide best-in-class solutions to the research community and an excellent entry point to supporting Epigenetics research."
Sigma-Aldrich plans to launch a family of products for Epigenetic research, beginning with the Imprint DNA Modification Kit in June 2007. The Company aims to provide customers a complete Epigenetic solution from DNA purification and bisulfite conversion to detection. Other products launching under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek's technologies.
Epigentek offers procedures for Bisulfite DNA modification and chromatin immunoprecipitation. Their DNA modification technology provides DNA conversion for methylation analysis in less than two hours and requires only 50 picograms of starting DNA.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.